|
Getting your Trinity Audio player ready...
|
NEW YORK, September 1, 2026 — Micro-cap and emerging-growth stocks GoPro, Inc. (NASDAQ: GPRO), Fly-E Group, Inc. (NASDAQ: FLYE), Cellyan Biotechnology Co., Ltd. (NASDAQ: HKPD) and VivoSim Labs, Inc. (NASDAQ: VIVS) are drawing investor attention across AI infrastructure, electric mobility, pharmaceutical supply chains and AI-powered drug development.
GoPro, Inc. (NASDAQ: GPRO) and privately held optical-photonics company Starman Optical, Inc. announced a definitive merger agreement that could significantly broaden GoPro’s business beyond consumer cameras. Under the proposed transaction, GoPro shareholders are expected to receive an aggregate $285 million in cash, or approximately $1.14 per share, subject to adjustment, while retaining approximately 10% ownership of the combined company. Starman’s U.S.-made optical transceivers are expected to expand GoPro’s exposure to AI data centers, government, defense and aerospace markets, while GoPro is expected to remain publicly listed on Nasdaq.
Fly-E Group, Inc. (NASDAQ: FLYE) is an electric-vehicle company focused on designing, selling and renting electric motorcycles, e-bikes and related electric mobility products under the Fly E-Bike brand. Fly-E reported approximately $19.1 million in fiscal 2026 net revenue, including significant growth in its wholesale and rental businesses, as it continues targeting demand for urban electric transportation.
Cellyan Biotechnology Co., Ltd. (NASDAQ: HKPD) operates in the cross-border OTC pharmaceutical market through two primary businesses: e-commerce pharmaceutical supply-chain services through Joint Cross Border Logistics Company Limited and OTC pharmaceutical procurement and distribution through V-Alliance Technology Supplies Limited. Its operations connect pharmaceutical suppliers, logistics providers and merchants serving China’s growing cross-border e-commerce market.
VivoSim Labs, Inc. (NASDAQ: VIVS) uses NAMkind™ 3D human liver and intestinal models with AI-powered predictive toxicology to help pharmaceutical companies identify stronger drug candidates earlier, addressing a development process where 5,000–10,000 compounds may ultimately yield just one approved drug. The company recently reported approximately $10.1 million in cash, supported in part by a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY) related to a previously divested drug program.
Together, GPRO, FLYE, HKPD and VIVS give micro-cap investors exposure to four distinct developing themes: AI data-center optics, electric mobility, pharmaceutical e-commerce and AI-enabled human drug testing.
About the Companies
GoPro, Inc. (NASDAQ: GPRO) develops cameras, imaging technologies, software and subscription services and, through its proposed combination with Starman Optical, is seeking to expand into optical technologies serving AI infrastructure and other strategic markets.
Fly-E Group, Inc. (NASDAQ: FLYE) designs, sells and rents electric motorcycles, e-bikes and related electric mobility products under the Fly E-Bike brand.
Cellyan Biotechnology Co., Ltd. (NASDAQ: HKPD) provides cross-border OTC pharmaceutical supply-chain, procurement and distribution services primarily through its Hong Kong subsidiaries.
VivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with NAMkind™ 3D human liver and intestinal models and AI-powered predictive toxicology designed to support drug-development decisions.
About The Street Reports
The Street Reports (TSR) a financial media platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.